Pharmacokinetics and dose selection of the 2-and 3-direct acting antiviral combination of AL-335 and odalasvir with/without simeprevir in hepatitis C virus-infected patients

被引：0
|
作者：
Kakuda, Thomas [1 ]
Ouwerkerk-Mahadevan, Sivi [2 ]
Ackaert, Oliver [2 ]
Valade, Elodie [2 ]
McClure, Matthew W. [1 ]
Westland, C. [1 ]
Vuong, J. [1 ]
Gane, Edward J. [3 ]
Fry, J. [1 ]
Chanda, Sushmita M. [1 ]
机构：
[1] Alios BioPharma Inc, San Francisco, CA USA
[2] Janssen Pharmaceut NV, Janssen Res & Dev, Beerse, Belgium
[3] Univ Auckland, New Zealand Liver Transplant Unit, Auckland, New Zealand
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1192
引用
收藏
页码：642A / 643A
页数：2
相关论文
共 40 条
  • [1] In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir
    Vijgen, L.
    Fevery, B.
    Jekle, A.
    Shaw, K.
    Tan, H.
    Lenz, O.
    Symons, J.
    De Meyer, S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S533 - S534
  • [2] Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects
    Kakuda, Thomas N.
    McClure, Matthew W.
    Westland, Christopher
    Vuong, Jennifer
    Homery, Marie-Claude
    Poizat, Gwendoline
    Viguerie, Laure
    Denot, Caroline
    Patat, Alain
    Zhang, Qingling
    Hui, James
    Apelian, David
    Smith, David B.
    Chanda, Sushmita M.
    Fry, John
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2018, 6 (03):
  • [3] Pharmacokinetics (PK), safety and tolerability of the 2-and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs)
    Kakuda, Thomas
    McClure, Matt
    Westland, Chris
    Vuong, Jennifer
    Homery, Marie-Claude
    Poizat, Gwendoline
    Viguerie, Laure
    Denote, Caroline
    Patat, Alain A.
    Zhang, Qingling
    Hui, James
    Apelian, David
    Smith, David B.
    Chanda, Sushmita
    Fry, John
    HEPATOLOGY, 2016, 64 : 728A - 728A
  • [4] JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1
    Zeuzem, Stefan
    Bourgeois, Stefan
    Greenbloom, Susan
    Buti, Maria
    Aghemo, Alessio
    Lampertico, Pietro
    Janczewska, Ewa
    Lim, Seng Gee
    Moreno, Christophe
    Buggisch, Peter
    Tam, Edward
    Corbett, Chris
    Willems, Wouter
    Vijgen, Leen
    Fevery, Bart
    Ouwerkerk-Mahadevan, Sivi
    Ackaert, Oliver
    Beumont, Maria
    Kalmeijer, Ronald
    Sinha, Rekha
    Biermer, Michael
    HEPATOLOGY, 2019, 69 (06) : 2349 - 2363
  • [5] Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naive patients with hepatitis C infection with or without cirrhosis
    Gane, E.
    Stedman, C.
    McClure, M.
    Apelian, D.
    Westland, C.
    Vuong, J.
    Patel, M.
    Kakuda, T.
    Chanda, S.
    Blatt, L.
    Beigelman, L.
    Smith, D.
    Fry, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S82 - S82
  • [6] Evaluation of the efficacy and tolerability of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study
    Zeuzem, Stefan
    Bourgeois, Stefan
    Greenbloom, Susan
    Buti, Maria
    Aghemo, Alessio
    Janczewska, Ewa
    Lim, Seng Gee
    Corbett, Chris
    Willems, Wouter
    Vijgen, Leen
    Ouwerkerk-Mahadevan, Sivi
    Beumont, Maria
    Sinha, Rekha
    Kalmeijer, Ronald
    Biermer, Michael
    HEPATOLOGY, 2017, 66 : 38A - 38A
  • [7] Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects
    McClure, Matthew W.
    Berliba, Elina
    Tsertsvadze, Tengiz
    Streinu-Cercel, Adrian
    Vijgen, Leen
    Astruc, Beatrice
    Patat, Alain
    Westland, Christopher
    Chanda, Sushmita
    Zhang, Qingling
    Kakuda, Thomas N.
    Vuong, Jennifer
    Khorlin, Nick
    Beigelman, Leonid
    Blatt, Lawrence M.
    Fry, John
    PLOS ONE, 2018, 13 (10):
  • [8] Virology analyses from HCV-infected patients treated with the combination of AL-335 and odalasvir, with and without simeprevir in Phase II studies
    Vijgen, Leen
    Fevery, Bart
    Biermer, Michael
    McClure, Matthew W.
    Sinha, Rekha
    Willems, Wouter
    Corbett, Chris
    Liu, Chris
    Augustyns, Ilse
    Chen, Li
    Gane, Edward J.
    Zeuzem, Stefan
    Moreno, Christophe
    Buggisch, Peter
    Tam, Edward
    De Meyer, Sandra
    HEPATOLOGY, 2017, 66 : 637A - 637A
  • [9] Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System
    Tan, Hua
    Shaw, Kenneth
    Kong, Hyunsoon
    Wang, Guangyi
    Beigelman, Leonid
    Smith, David B.
    Blatt, Lawrence M.
    Symons, Julian
    HEPATOLOGY, 2016, 64 : 727A - 727A
  • [10] Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures
    Pawlotsky, Jean-Michel
    SEMINARS IN LIVER DISEASE, 2019, 39 (03) : 354 - 368
1234